Tweet
Sci Adv
. 2023 Aug 4;9(31):eadg2122.
doi: 10.1126/sciadv.adg2122. Epub 2023 Aug 4. Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13
Marne Azarias Da Silva 1 , Pierre Nioche 1 2 , Calaiselvy Soudaramourty 1 , Anne Bull-Maurer 3 , Mounira Tiouajni 1 2 , Dechuan Kong 4 5 , Ouafa Zghidi-Abouzid 6 , Morgane Picard 1 , Ana Mendes-Frias 7 8 , André Santa-Cruz 7 8 9 , Alexandre Carvalho 7 8 9 , Carlos Capela 7 8 9 , Jorge Pedrosa 7 8 , António Gil Castro 7 8 , Paul Loubet 10 , Albert Sotto 10 , Laurent Muller 11 , Jean-Yves Lefrant 11 , Claire Roger 11 , Pierre-Géraud Claret 12 , Sandra Duvnjak 13 , Tu-Anh Tran 14 , Kenzo Tokunaga 5 , Ricardo Silvestre 7 8 , Pierre Corbeau 15 16 , Fabrizio Mammano 1 3 , Jérôme Estaquier 1 6
Affiliations
Since the initial spread of severe acute respiratory syndrome coronavirus 2 infection, several viral variants have emerged and represent a major challenge for immune control, particularly in the context of vaccination. We evaluated the quantity, quality, and persistence of immunoglobulin G (IgG) and IgA in individuals who received two or three doses of messenger RNA (mRNA) vaccines, compared with previously infected vaccinated individuals. We show that three doses of mRNA vaccine were required to match the humoral responses of preinfected vaccinees. Given the importance of antibody-dependent cell-mediated immunity against viral infections, we also measured the capacity of IgG to recognize spike variants expressed on the cell surface and found that cross-reactivity was also strongly improved by repeated vaccination. Last, we report low levels of CXCL13, a surrogate marker of germinal center activation and formation, in vaccinees both after two and three doses compared with preinfected individuals, providing a potential explanation for the short duration and low quality of Ig induced.
. 2023 Aug 4;9(31):eadg2122.
doi: 10.1126/sciadv.adg2122. Epub 2023 Aug 4. Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13
Marne Azarias Da Silva 1 , Pierre Nioche 1 2 , Calaiselvy Soudaramourty 1 , Anne Bull-Maurer 3 , Mounira Tiouajni 1 2 , Dechuan Kong 4 5 , Ouafa Zghidi-Abouzid 6 , Morgane Picard 1 , Ana Mendes-Frias 7 8 , André Santa-Cruz 7 8 9 , Alexandre Carvalho 7 8 9 , Carlos Capela 7 8 9 , Jorge Pedrosa 7 8 , António Gil Castro 7 8 , Paul Loubet 10 , Albert Sotto 10 , Laurent Muller 11 , Jean-Yves Lefrant 11 , Claire Roger 11 , Pierre-Géraud Claret 12 , Sandra Duvnjak 13 , Tu-Anh Tran 14 , Kenzo Tokunaga 5 , Ricardo Silvestre 7 8 , Pierre Corbeau 15 16 , Fabrizio Mammano 1 3 , Jérôme Estaquier 1 6
Affiliations
- PMID: 37540749
- DOI: 10.1126/sciadv.adg2122
Since the initial spread of severe acute respiratory syndrome coronavirus 2 infection, several viral variants have emerged and represent a major challenge for immune control, particularly in the context of vaccination. We evaluated the quantity, quality, and persistence of immunoglobulin G (IgG) and IgA in individuals who received two or three doses of messenger RNA (mRNA) vaccines, compared with previously infected vaccinated individuals. We show that three doses of mRNA vaccine were required to match the humoral responses of preinfected vaccinees. Given the importance of antibody-dependent cell-mediated immunity against viral infections, we also measured the capacity of IgG to recognize spike variants expressed on the cell surface and found that cross-reactivity was also strongly improved by repeated vaccination. Last, we report low levels of CXCL13, a surrogate marker of germinal center activation and formation, in vaccinees both after two and three doses compared with preinfected individuals, providing a potential explanation for the short duration and low quality of Ig induced.